Parent-Led Cognitive-Behavioral Teletherapy for Anxiety in Youth With ASD

Sponsor
Baylor College of Medicine (Other)
Overall Status
Active, not recruiting
CT.gov ID
NCT04111874
Collaborator
(none)
190
1
2
38
5

Study Details

Study Description

Brief Summary

This study implements an anxiety-focused, parent-led, therapist-assisted cognitive behavioral teletherapy for parents of youth with ASD and anxiety.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Cognitive Behavioral Teletherapy LTA
  • Behavioral: Cognitive Behavioral Teletherapy STA
N/A

Detailed Description

Anxiety disorders affect 50-80% of children with autism spectrum disorder (ASD) and are associated with significant life impairment and worsening trajectory without treatment. The most effective psychotherapy for anxiety in youth with and without ASD is cognitive behavioral therapy (CBT), but many families are not able to access CBT due to the cost, practicalities of attending treatment sessions, and limited availability of trained therapists. Alternative models of service delivery are greatly needed, with particular promise of parent-led therapist-assisted (PLTA) models and telehealth delivery formats. Parents may benefit from additional information regarding how to optimize the delivery of CBT for youths with ASD given the potential impact of ASD symptomology on core CBT skills. Thus, this project aims to improve access to anxiety-focused Parent-Led Therapist-Assisted CBT for parents of youth with ASD. Parent-led low-intensity treatment models can improve accessibility, efficiency, and mental health treatment cost. Lower intensity treatment models provide a treatment option that is less costly and burdensome for parents; it is understood that some individuals will respond to the first step and others will require additional treatment to achieve anxiety reduction. However, understanding how many families, and which families, can benefit from a lower intensity model has dramatic benefits for improving access, allocating more intensive services for those most in need, and reducing barriers (e.g., distance). Thus, this study will examine the effectiveness of two anxiety-focused PTLA CBT telehealth models: 1) low-intensity therapist assistance (LTA) and 2) standard therapist assistance (STA). Overall, this study will provide important information regarding the potential benefits of two different approaches to parent-led interventions for youth with ASD and anxiety when delivered via telehealth.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
190 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Parent-Led Cognitive-Behavioral Teletherapy for Anxiety in Youth With ASD
Actual Study Start Date :
Jul 30, 2019
Anticipated Primary Completion Date :
May 31, 2022
Anticipated Study Completion Date :
Sep 30, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Low-Intensity Therapist Assistance (LTA)

Parents will receive four 30-minute supportive video calls with a therapist over the 12 weeks of treatment.

Behavioral: Cognitive Behavioral Teletherapy LTA
Participating families will receive a copy of the book 'Helping Your Anxious Child, 2nd Edition', as well as the companion parent and child workbooks, to use at home and in session with the therapist. During each of the four videoconferencing sessions, therapists will serve to provide encouragement and support as the parent works through the program independently.

Active Comparator: Standard Therapist Assistance (STA)

Parents will receive ten 60-minute supportive video calls with a therapist over the 12 weeks of treatment.

Behavioral: Cognitive Behavioral Teletherapy STA
Participating families will also receive a copy of the book 'Helping Your Anxious Child, 2nd Edition', as well as the companion parent and child workbooks, to use at home and in session with the therapist. During each of the ten videoconferencing sessions, therapists will guide the parent through the implementation of the program, including explaining materials, assisting to develop planned therapy activities with the child, and problem-solving as needed.

Outcome Measures

Primary Outcome Measures

  1. 6-item Pediatric Anxiety Rating Scale [7 days]

    Clinician rated child anxiety severity throughout the past week. Each item is scored on a 0 to 5 scale (higher scores correspond to greater severity), yielding a total between 0 and 30.

  2. Clinical Global Impression-Improvement [7 days]

    Clinician rated child psychopathology improvement since initial rating. A single item is scored 0-6 (0 = very much worse; 6= very much improved).

Secondary Outcome Measures

  1. Clinical Global Impression-Severity [7 days]

    Clinician rated child psychopathology severity rating. A single item is scored 0-6 (0= no illness; 6= extremely severe symptoms).

Eligibility Criteria

Criteria

Ages Eligible for Study:
7 Years to 13 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Child is between the ages 7-13 years at consent/assent.

  • The child meets criteria for ASD.

  • The child meets criteria for clinically significant anxiety and/or OCD symptoms.

  • Anxiety and/or OCD is the primary presenting problem.

  • One parent/guardian is able and willing to participate.

  • The child has a Full Scale and Verbal Comprehension Intelligence Quotient >70.

  • The child is able to communicate verbally.

  • Participants must reside in Texas and parents must be in the state of Texas when taking calls.

Exclusion Criteria:
  • The child has a diagnosis of lifetime DSM-5 bipolar disorder, psychotic disorder, and/or intellectual disability.

  • The child has severe current suicidal/homicidal ideation and/or self-injury requiring medical intervention.

  • The child is receiving concurrent psychotherapy for anxiety.

  • Initiation of a psychotropic medication less than 4 weeks prior to study enrollment or a stimulant/psychoactive medication less than 2 weeks prior to study enrollment.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Baylor College of Medicine Houston Texas United States 77030

Sponsors and Collaborators

  • Baylor College of Medicine

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Eric A Storch, Principal Investigator, Baylor College of Medicine
ClinicalTrials.gov Identifier:
NCT04111874
Other Study ID Numbers:
  • H45203
First Posted:
Oct 1, 2019
Last Update Posted:
Feb 1, 2022
Last Verified:
Jan 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 1, 2022